Background: Several studies have focused on the relationship between MMP-8 variants and cancer risk, but they have been unsuccessful in drawing reliable conclusions. Methods: We employed odds ratio (OR) together with 95% confidence interval (CI) to assess the correlation between MMP-8 C-799 T, Lys460Thr, and Lys87Glu polymorphisms and cancer risk. We further employed in silico tools to evaluate the effect of MMP-8 expression on cancer susceptibility and overall survival time.
Background
It is well-known that the development of carcinoma is complex and has not been completely clarified. Hereditary material and genetic polymorphisms may probably have an impact on cancer susceptibility and play a crucial role in the tumorigenesis of numerous carcinomas [1] [2] [3] [4] . Previous studies have shown evidence that the genetic aspects measured by single nucleotide polymorphisms (SNPs) might be associated with cancer susceptibility [5] [6] [7] [8] . Matrix metalloproteinases (MMPs) belong to a family of endopeptidases that can degrade various extracellular matrix proteins and treat numerous extracellular matrix (ECM) components [9, 10] . Accumulated evidence has indicated that MMPs may have a critical role in cell inflammation, migration and carcinogenesis [11] [12] [13] . Increased levels of MMPs have been observed in the specimens of a number of cancer subjects, such as urinary bladder cancer, lung cancer, breast cancer, and malignant melanoma [14] . Among the MMPs, MMP8 is a collagen-cleaving enzyme present in connective tissue. The MMP8 is not only produced by neutrophils but also synthesized by a series of malignant tumor cells [15, 16] . High level of MMP8 was reported in the fluid of ovarian cancer compared to control tissue [17] .
Previous studies have showed evidence that genetic mutations and variants can predispose for malignant tumors [18, 19] . Human MMP-8 gene comprises twelve exons and is located on chromosome 11q22.3 [20] . Polymorphisms of MMP8 can lead to gene dysfunction, microenvironment disorder and potential carcinogenesis. It has been reported that several single nucleotide polymorphisms (SNPs) of MMP8 can influence the gene expression by altering its promoter activity. In addition, the T allele of MMP8 C-799 T variant was reported to be related to breast carcinoma susceptibility and lymph node metastasis among Asian and Caucasian population [21] . Furthermore, electrophoresis mobility shift assays have demonstrated that the difference in nucleoprotein binding to oligodeoxynucleotides was correlated with MMP8 C-799 T variation [22] . However, Wieczorek et al. indicated that genetic variation in MMP8 C-799 T was not associated with urinary bladder cancer susceptibility in Caucasian descendants [23] .
A number of studies have evaluated the association of MMP8 genetic variants including C-799 T (rs11225395 C/T), Lys460Thr (rs35866072 A/C), and Lys87Glu (rs1940475 G/A) SNPs, with cancer risk. Research on these MMP8 variations have been carried out in numerous countries, such as USA, Mexico, Poland, India, Korea, and China [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Nevertheless, there were controversial results on the relationship between MMP8 variations and various cancers among different case control studies. Therefore, we conducted a comprehensive analysis based on accumulated data of all eligible studies to investigate the impact of MMP-8 C-799 T, Lys460Thr, and Lys87Glu polymorphisms on overall cancer susceptibility.
Methods

Database searching and screening process
Comprehensive literature search on PubMed, Web of Science, EMBASE (Excerpta Medica Database), and SinoMed (China Wanfang Databases) was carried out to identify all eligible case-control studies, prior to June 2019. Valid keyword search strings are as follows: (MMP-8 OR matrix metalloproteinases 8) AND (polymorphism OR variant OR mutation OR SNP) AND (carcinoma OR tumor OR malignancy OR cancer). Furthermore, we independently retrieved the references in the identified articles to screen other available studies, with no language restriction. For studies with overlapping data, we selected the most recently published ones.
Inclusion and exclusion criteria
Eligible studies should meet the following inclusion criteria: (a) evaluate the relationship between MMP-8 C-799 T, Lys460Thr, and Lys87Glu polymorphisms and cancer risk; (b) case-control study; and (c) contain available data on the frequency of genotypes. We independently excluded unpublished case reports, letters, reviews, meta-analyses, or missing genotype data for C-799 T, Lys460Thr, and Lys87Glu variants. We also excluded the studies that focused only on the case population.
Data extraction and quality assessment
Two authors (LFZ and YYM) independently completed the data extraction based on the selection criteria. Any potential disagreement was discussed comprehensively to obtain a final consensus. The main features of included studies are summarized, which includes: first author's name, year of publication, origin and race, type of cancer, age range, total number of participants, genotyping assay of MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants in cases and controls, P-value of Hardy-Weinberg equilibrium (HWE) in controls. The quality score of the eligible studies was evaluated by Newcastle-Ottawa Scale (NOS). The research was regarded as high-quality if it acquired six or more stars.
Statistical analysis
We calculated the OR with 95% CI to investigate the strength of the relationship between MMP-8 C-799 T, Lys460Thr, and Lys87Glu polymorphisms and cancer susceptibility. A total of five genetic models were adopted: allelic contrast (M-allele vs. W-allele, for C-799 T, T vs. C; for Lys460Thr, C vs. A; for Lys87Glu, A vs. G), homozygote model (MM vs. WW, for C-799 T, TT vs. CC; for Lys460Thr, CC vs. AA; for Lys87Glu, AA vs. GG), heterozygote model (MW vs. WW, for C-799 T, TC vs. CC; for Lys460Thr, CA vs. AA; for Lys87Glu, AG vs. GG), dominant comparison (MM + MW vs. WW, for C-799 T, TT + TC vs. CC; for Lys460Thr, CC+ CA vs. AA; for Lys87Glu, AA + AG vs. GG), recessive comparison (MM vs. MW + WW, for C-799 T, TT vs. TC + CC; for Lys460Thr, CC vs. CA + AA; for Lys87Glu, AA vs. AG + GG). Q-test was utilized to estimate the heterogeneity among enrolled researches. If the heterogeneity was absent (P > 0.05), the fixed-effects model was employed [36] ; alternatively, the random-effects model was performed [37] . Stratified analyses were carried out according to race (Asian, Caucasian, and Latin), type of cancer (bladder cancer and other cancers), and source of control. Hardy-Weinberg equilibrium (HWE) in the control group was calculated using a Chi-squared test. Begg's funnel plot and the Egger's test were both performed to measure the possible publication bias. P values of Begg's and Egger's test more than 0.05 indicated the absence of publication bias. The STATA software (Version 11.0, Stata Corporation, College Station, TX, USA) was adopted for all the above analyses. 
In silico analysis of MMP-8
To further investigate whether the expression of MMP-8 has an impact on tumorigenesis, we employed the online TCGA database to evaluate the MMP-8 expression in bladder cancer tissue and control counterparts. The effect of the expression of MMP-8 on bladder cancer patients' overall survival time was also assessed. Furthermore, we adopted bioinformatics tools, like Polyphen-2 (http://genetics.bwh.harvard. edu/pph2/), to predict the role of MMP-8 SNPs at the protein level.
Results
Characteristics of included studies
Main characteristics of the eligible articles as well as the genotyping assay results of MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants have been summarized in Table 1 . A total of 13 publications containing 19 case-control studies for the MMP-8 polymorphisms in compliance with the inclusion criteria were finally identified in the present analysis. All eligible studies had NOS score more than 6. There were 4372 cancer patients and 5066 control participants for the analysis of MMP-8 C-799 T variant. Five articles were acquired for assessing the association of MMP-8 Lys460Thr variant on cancer susceptibility, including 3019 cases and 3544 control subjects. There were 749 cases and 1919 controls on the Lys87Glu polymorphism. The MAFs (minor allele frequencies) of MMP-8 C-799 T variants were shown in Fig. 1 : African, 0.185; East Asian, 0.423; European, 0.411; South Asian, 0.350; and American, 0.440. For MMP-8 Lys460Thr polymorphism: African, 0.222; East Asian, 0.009; European, 0.044; South Asian, 0.060; and American, 0.060. The MAFs for Lys87Glu variant were: African, 0.290; East Asian, 0.432; European, 0.453; South Asian, 0.400; and American, 0.480. In stratified analysis by race, 13 case-control studies were conducted on Asian descendants; five were based on the Caucasian population and one was based on Latin descendants. In stratified analysis by cancer type, four studies concerned bladder cancer. The rest were focused on other cancers, such as lung cancer, hepatocellular carcinoma, malignant melanoma, oral cancer, ovary cancer, and gastric cancer. In stratified analysis by the source of control, 12 studies were population-based controls, and the rest seven were hospital-based studies.
Quantitative synthesis
Summarized results and details of the present analyses for the three MMP-8 polymorphisms and cancer risk are provided in Table 2 . Overall analysis indicated that the relationship between the three MMP-8 variants and cancer susceptibility was not significant. The MMP-8 C-799 T variant is not associated with the susceptibility of cancer under all genetic models (allele contrast: OR = 0.98, 95% CI = 0.92-1.04, P heterogeneity = 0.068, P = 0.429; TT vs. CC: OR = 0.94, 95% CI = 0.82-1.07, P heterogeneity = 0.097, P = 0.362; heterozygote comparison: OR = 1.00, 95% CI = 0.92-1.09, P heterogeneity = 0.193, P = 0.992; TT + TC vs. CC: OR = 0.98, 95% CI = 0.90-1.07, P heterogeneity = 0.086, P = 0.666; recessive model: OR = 0.94, 95% CI = 0.83-1.07, P heterogeneity = 0.249, P = 0.348). In subgroup analysis by cancer type, we also indicated no relationship between MMP-8 C-799 T variant and bladder cancer (T vs. C: OR = 0.97, 95% CI = 0.83-1.12, P = 0.671, Fig. 2 ; TT vs. CC: OR = 0.85, 95% CI = 0.61-1.17, P = 0.316; TC vs. CC: OR = 1.08, 95% CI = 0.87-1.33, P = 0.492; TT + TC vs. CC: OR = 1.02, 95% CI = 0.84-1.25, P = 0.813; TT vs. TC + CC: OR = 0.83, 95% CI = 0.61-1.12, P = 0.219) or other cancers (T vs. C: OR = 0.99, 95% CI = 0.89-1.11, P = 0.898; TT vs. CC: OR = 0.96, 95% CI = 0.83-1.11, P = 0.578; TC vs. CC: OR = 0.99, 95% CI = 0.89-1.09, P = 0.763; TT + TC vs. CC: OR = 1.00, 95% CI = 0.86-1.16, P = 0.965; TT vs. TC + CC: OR = 0.97, 95% CI = 0.84-1.11, P = 0.631). In stratified analysis by race and source of control, no significant association between this polymorphism and cancer susceptibility was demonstrated ( Fig. 3 ). For the MMP-8 Lys460Thr variant, we also indicated no major association of this variant on cancer risk (C vs. A: OR = 0.94, 95% CI = 0.67-1.32, P heterogeneity = 0.905, P = 0.729; CC vs. AA: OR = 0.83, 95% CI = 0.36-1.93, P heterogeneity = 0.859, P = 0.669; CA vs. AA: OR = 1.00, 95% CI = 0.66-1.50, P heterogeneity = 0.904, P = 0.994; TT + TC vs. CC: OR = 0.96, 95% CI = 0.67-1.40, P heterogeneity = 0.886, P = 0.848; recessive model: OR = 0.83, 95% CI = 0.36-1.93, P heterogeneity = 0.866, P = 0.669, Table 2 ). In addition, similar results were revealed for the association between the MMP-8 Lys87Glu variant and cancer risk in allelic contrast (OR = 1.05, 95% CI = 0.93-1.18, P value for heterogeneity = 0.968, P = 0.430); homozygote model (OR = 1.11, 95% CI = 0.88-1.42, P heterogeneity = 0.953, P = 0.377); heterozygote comparison (OR = 0.96, 95% CI = 0.78-1.18, P value for heterogeneity = 0.647, P = 0.722); dominant model (OR = 1.01, 95% CI = 0.83-1.22, P heterogeneity = 0.863, P = 0.928), and recessive comparison (OR = 1.13, 95% CI = 0.93-1.38, P heterogeneity = 0.604, P = 0.222).
In silico analysis of MMP-8
Results from the TCGA database, containing 408 primary tumor and 19 normal samples, revealed that MMP-8 expression was elevated in bladder cancer tissue as compared to their control counterpart (P < 0.01, Fig. 4a ). Furthermore, we investigated whether the MMP-8 expression had an effect on the overall survival time of bladder carcinoma participants. However, neither higher MMP-8 expression group nor lower expression group would have an impact on the patients' overall survival time (P < 0.05, Fig. 4b, c ). In addition, we adopted the Polyphen-2 bioinformatics tool to analyze the associations between MMP-8 Lys460Thr (K460 T, rs35866072), and Lys87Glu (K87E, rs1940475) variants and protein damage. Mutations of these SNPs are predicted to be "BENIGN" with a score less than 0.05, which indicated that neither Lys460Thr nor Lys87Glu SNP may probably damage the protein of MMP-8 ( Fig. 5 ).
Publication bias
Both Egger's and Begg's funnel plot were employed for appraisal of the publication bias when evaluating MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants. No evidence of publication bias was acquired for MMP-8 C-799 T polymorphism (T-allele vs. C-allele, (Fig. 6 ).
Discussion
The MMP-8 serves as one of the most efficient collagenases and plays an essential role in carcinoma invasion and metastasis. Previous research demonstrated that advanced metastatic stage and further poor prognosis of carcinoma might be related to elevated expression of MMPs [38, 39] . Additionally, it was hypothesized that the regulatory effect of MMPs could be associated with variations in the MMP genes. One group reported that the MMP8 C-799 T variant might be related to breast carcinoma susceptibility and lymph node metastasis in Asians and Caucasians [21] . However, another group investigated MMP8 variations among a representative Taiwanese breast carcinoma population and indicated no significant relationship between MMP-8 C-799 T, and Lys460Thr polymorphisms and cancer risk [34] . Therefore, it is reasonable to summarize all eligible data and draw more accurate conclusions to evaluate the contribution of MMP-8 polymorphisms to cancer risk. Furthermore, we employed the TCGA database and Polyphen2 bioinformatics tools to assess the role of MMP-8 expression on cancer risk and survival time.
In the present study, a total of 8140 patients with malignant carcinoma and 10,529 control participants [23, 31, 34] . In subgroup analysis by cancer type, this variation did not significantly confer susceptibility to urinary bladder cancer (zvalue = 0.43, P heterogeneity = 0.286, P = 0.671) and other cancers (z-value = 0.13, P heterogeneity = 0.039, P = 0.898). In stratified analysis by race, a similar result was indicated in Asian (z-value = 1.54, P heterogeneity = 0.248, P = 0.125) and Caucasian descendants (z-value = 1.87, P heterogeneity = 0.082, P = 0.062). For MMP-8 Lys460Thr variant, no positive correlation was found in the overall analysis (z-value = 0.35, P heterogeneity = 0.905, P = 0.729). Similar results were indicated for Lys87Glu variant (z-value = 0.79, P heterogeneity = 0.968, P = 0.430). Results from in silico analysis showed that MMP-8 expression was elevated in bladder cancer tissue as compared to the control counterpart. However, both the higher and lower MMP-8 expression groups did not have an impact on the patients' overall survival time. Moreover, Polyphen-2 bioinformatics tool was also adopted to confirm the results of our present analysis. As the report for MMP-8 C-799 T (rs11225395) variation was not available, the association between Lys460Thr (K460 T, rs35866072), and Lys87Glu (K87E, rs1940475) variants and protein damaging was further investigated. Mutations of Lys460Thr and Lys87Glu were predicted to be "BENIGN" with a score less than 0.05, which indicated that these SNPs do not damage MMP-8 protein, and are in agreement with the conclusions of the current analyses.
In addition, several limitations of the present study should be clarified. First of all, the number of enrolled studies for subgroup analysis remains insufficient, which exhibits fairly limited statistical power. Only five studies for MMP-8 Lys460Thr SNPs and three for Lys87Glu polymorphism were acquired based on the selection criteria. As regard to C-799 T variant, only two case-control studies were focused on Caucasian population and one was based on Latin descendants. In addition, tumor stage and grade may potentially influence the results of the present analysis. We tried to further evaluate this effect in more details; however, raw data of eligible studies remains insufficient. More efficient investigations are still required to further strengthen the statistical power. Last but not least, P value for HWE was less than 0.05 in five of the included articles [30, 31, [33] [34] [35] , which might be exposed to unknown bias factors.
Despite these limitations, some key advantages should be acknowledged. First, all eligible case-control studies according to the selection criteria were obtained and the statistical efficiency was enhanced remarkably. Second, no obvious publication bias was indicated by Egger's and Begg's funnel plot, which showed that the findings of the current analysis can be considered reliable. Additionally, NOS scores of the enrolled studies were more than 6, which indicated a high methodological quality of each article.
Conclusions
Taken together, based on the currently published data, our study showed evidence that MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants are not participant with the susceptibility of cancer. Further well-designed investigations are still warranted to confirm this conclusion in more detail. 
